Henrik Jarlov

Henrik Jarlov

Novo Nordisk A S - Bagsvaerd / Denmark
Others
AD Scientific Index ID: 5575262
person_outline Henrik Jarlov's MOST POPULAR ARTICLES
1-) Safety and efficacy of insulin degludec/liraglutide (ID egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the … Diabetic Medicine 34 (2), 189-196, 2017
2-) A novel nonsense mutation in PAX9 is associated with marked variability in number of missing teeth European Journal of Oral Sciences 115 (4), 330-333, 2007
3-) Type 2 diabetes patients reach target glycemic control faster using IDegLira than either insulin degludec or liraglutide given alone Clinical Drug Investigation 36, 293-303, 2016
4-) Type 2 diabetes patients reach target glycemic control faster using IDegLira than either insulin degludec or liraglutide given aloneT Vilsbøll, J Vora, H Jarlov, K Kvist, L BlondeClinical Drug Investigation 36, 293-303, 2016152016
5-) IDegLira in insulin-naïve patients with type 2 diabetes (T2D) inadequately controlled on sulfonylureas (SU) alone or in combination with metformin: the DUAL IV studyHW Rodbard, BW Bode, SB Harris, L Rose, L Lehmann, H Jarlov, ...Diabetes 64, A255-A256, 2015152015